Our attorneys have handled a range of matters related to licensing, intellectual property, mergers and acquisitions and financing.

Licensing and Commercialization

Among our licensing and commercialization matters, we have represented:

  • Penn Pharmaceutical Services (a U.K. company) on its agreements with several biotechnology and pharmaceutical companies.
  • An international medical device company in dozens of product license, distribution, manufacturing and reseller arrangements worldwide.
  • Edge Therapeutics on the in-license of a drug delivery system from SurModics.
  • U.S. patent for Medtronic directed to methods and devices for the treatment of intervertebral discs.
  • PluroGen Therapeutics, an early stage biotechnology company that provides clinically advanced burn, wound and skin care products, in connection with a significant equity investment from and entering into a distribution agreement with Medline, Inc., a privately held manufacturer and distributor of medical devices and health care products.
  • Public and private universities and hospital-based research institutions in licensing matters.
  • A major Korean health care company in reaching an agreement with a widely held U.S. public company in patent licensing and joint development of intellectual property.
  • A U.S.-based provider of software in connection with a joint venture arrangement in Asia and several licensing and reseller arrangements for this software worldwide.
  • A provider of data analytics services in licensing its technology to several major telecommunications service providers.
  • An e-commerce solutions provider in developing its patent portfolio and ensuring that its software was properly owned or licensed.
  • A global online gaming service in licensing its technology as an over-the-top service to a cable television service provider.
  • NeuroFix Therapeutics, Inc. in its license of certain innovative technology related to the treatment of certain neurological diseases from the Children’s Hospital of Pennsylvania.
  • A clinical software company in connection with the license of its proprietary patient management, site monitoring and clinical outcomes software to customers.
  • An agricultural technology startup company with licensing its proprietary fertilizer and soil amendment products based on recycled green organic waste. In addition, assisted with supply contracts for the green organic waste needed for manufacturing.

Intellectual Property

  • Helped an educational software company develop a strategy for leveraging open source code while still developing a separate code set that remained proprietary. Supported the company in negotiations and due diligence review in connection with its sale to a company that is a global leader in student learning technology.
  • Developed a patent portfolio for a commercial robotic cleaning equipment company and supported a transaction in which the company was acquired by one of the world’s largest manufacturers of institutional cleaning and hygiene products.
  • Represented an Israel-based company that developed innovative software for visualizing data in the sale of its intellectual property assets to a global software company.
  • Helped develop patent portfolio of an Internet mobilization software provider that was acquired by a U.S. telecommunications company.
  • Represented a computer security software company in intellectual property due diligence for its acquisition of mobile device security solutions provider.
  • Provided intellectual property support to an e-commerce solutions provider in a transaction in which the company was acquired by one of the world’s largest Internet-based retailers.

Mergers and Acquisitions

Among our mergers and acquisitions matters, we have represented:

  • PuraCap Pharmaceutical LLC, a New Jersey-based fully integrated pharmaceutical company, and its parent company Humanwell Healthcare Group Co., Ltd. (SHA: 600079), a China-based life sciences company, in their $550 million acquisition of Epic Pharma, LLC. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities.
  • RestorGenex Corporation (OTCQX:RESX), an Illinois-based public specialty biopharmaceutical company, in its merger with Virginia-based Diffusion Pharmaceuticals, a privately held clinical stage biotechnology company.
  • Healthcare Providers Insurance Exchange (HPIX), a top 10 insurer of physician commercial medical professional liability in the Mid-Atlantic, in an acquisition in which HPIX’s rights, title, interests and policies were acquired by Medical Mutual Insurance Company of North Carolina, a leading provider of medical professional liability for physicians in the Southeast.
  • The Chemistry Research Solution LLC (TCRS), a chemistry and bioconjugation company based near Philadelphia, in its acquisition by Abzena plc (AIM:ABZA), a British life sciences technology and services company, for $15 million. Under the terms of the deal, Abzena acquired TCRS for $8.8 million in cash, $1.5 million in assumed debt and the remainder in stock.
  • neuroFix Therapeutics, LLC, the developer of NFC-1, in its acquisition by Medgenics (NYSE: MDGN). Hakon Hakonarson, M.D., Ph.D., Professor and Director of the Center for Applied Genomics at The Children's Hospital of Philadelphia (CHOP) founded neuroFix to pursue development of NFC-1 following a breakthrough genetic discovery. Medgenics acquired all outstanding shares of neuroFix for upfront consideration of $2 million cash, a series of performance-based milestone payments and sales royalties.
  • AltheRx, Inc., a privately held, clinical development company focused on advancing best-in-class compounds, in its merger with and into the newly formed Velicept Therapeutics, Inc. The merger will allow the advancement of Solabegron, the company’s lead candidate for overactive bladder, which completed two Phase II studies.
  • An international medical device company, in all aspects of its U.S. and worldwide operations, including eight strategic acquisitions across the globe and the successful sale of the company to a large public company buyer for $120 million.
  • Enantigen Therapeutics, Inc., a privately held pharmaceutical company located at the Pennsylvania Biotechnology Center, in its acquisition by OnCore Biopharma, Inc., a biotechnology company focused on the research, development and commercialization of oral treatments for chronic hepatitis B virus (HBV) infection.
  • NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft-tissue microwave ablation systems, through a major acquisition by Ethicon Endo-Surgery, Inc., a medical device company, which is part of the Johnson & Johnson family of companies.
  • KonciergeMD, a cloud-based consumer engagement company, in its acquisition by Accolade.
  • Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, in its acquisition of Los Angeles-based Precision Health Economics, a health economics consultancy and analytics firm.
  • Lannett Company, Inc. (NYSE: LCI), a developer, manufacturer, marketer and distributor of generic pharmaceutical products, in its acquisition of the capital stock of privately held Silarx Pharmaceuticals, Inc., a manufacturer and marketer of liquid generic pharmaceutical products.
  • Clinigen Group plc (LSE: CLIN), a specialty global pharmaceutical company, in its:
    • £225 million acquisition of Idis Group Holdings Limited, the leading supplier for ethical on-demand products, with products in more than 120 different countries. Clinigen is the market leader in the more than $5 billion unlicensed medicine supplier sector and has a leading position in the $2 billion clinical trial supply market.
    • Acquisition of the global rights to the oncology support therapy Ethyol® (amifostine) from AstraZeneca.
  • Biomed America in its $100-million-plus stock sale to Allion Healthcare.
  • Health care company in its merger with a provider of specialized biopharmaceutical medications and services valued at $51.4 million.
  • Regional surgical monitoring company in its sale to a large private equity firm for approximately $40 million in transaction value.
  • Immunicon in the $30 million sale of its assets to a Johnson & Johnson Co. affiliate.
  • Moda Technology Partners, Inc. in the sale of all of its stock to Lonza, Inc., a Swiss publicly traded pharmaceutical company, in a transaction that represented more than a three-fold return on investment for the venture capital and other investors in Moda.
  • Switzerland-based Axxiome Group, a global information technology and solutions provider for the financial services industry, in its acquisition of J9 Technologies, Inc., an information technology and services company. The acquisition allows Axxiome to extend its reach and product portfolio in the North American market.
  • Gaming Laboratories International, LLC (GLI), a global leader in gaming testing and professional services, in its acquisition of SLI Global Solutions, Inc., a leader in quality assurance and software testing services. With this acquisition, SLI Global Solutions and GLI combined to form one of the largest software testing and quality assurance service providers.
  • Excel Micro, Inc., a distributor of cloud email security and archiving solutions, in its acquisition by j2 Global, Inc. (NASDAQ:JCOM), a global provider of Internet services. The acquisition expands j2’s U.S. and Canadian email security customer base, reseller channels and channel expertise.
  • UXC Eclipse, the leading global implementation partner for intelligent business solutions, in the acquisition of Tectura North America. This acquisition will allow UXC Eclipse, a business unit of Australian IT solutions and services company UXC Limited, to become one of the largest Microsoft Dynamics resellers in the Americas.
  • Talent Inc., an online career community and subsidiary of a Swedish holding company, in the acquisition of the assets of RezBiz, a leading provider of professional resume writing and LinkedIn makeover services. The transaction forms the largest resume writing service in the United States and enables Talent Inc. to expand its product offerings to new markets.


Among our financing matters, we have represented:

  • Clinigen Group plc (LSE: CLIN), a specialty global pharmaceutical company, in its £135 million U.K. initial public offering of pharmaceutical company.
  • Lannett Company, Inc. (NYSE: LCI), a developer, manufacturer, marketer and distributor of generic pharmaceutical products, in its public offering of stock by issuer and selling stockholders.
  • Medical Transcription Billing, Corp. (Nasdaq: MTBC), a leading provider of proprietary, web-based electronic health records, practice management and mHealth solutions, in its initial public offering of 4.08 million shares of common stock at $5 per share.
  • An international medical device company, in its private equity financings by European private equity firms.
  • Topaz Pharmaceuticals in a $20 million Series A preferred stock financing and two earlier rounds of seed funding totaling $3.5 million.
  • Synerx Pharmaceuticals, developer of five FDA-approved products, in its $10.5 million capital raise.
  • Innocutis, a dermatology products marketer, in its $6.5 million raise in equity capital from Ballast Point Ventures.
  • Trice Medical, a pioneer in needle-based diagnostic and therapeutic technologies for orthopedics, in a Series B Convertible Preferred Stock financing.
  • CRO Analytics, a clinical research company for the biopharmaceutical industry, on a Ben Franklin Partners Series A financing.
  • Rosemark Capital, a private equity firm that partners with tech companies in bringing new ideas and solutions to market, in its $23.5 million Series C funding of Jiff, the rapidly growing enterprise health benefits platform. The company released Jiff Navigator, a new tool that will help employers facing rising health care costs leverage data analytics and the latest health apps, wearables and programs to manage health benefits and reduce health care spending. The funding includes a strategic investment from GE Ventures as well as investments from Venrock Associates, Aberdare Partners and Aeris Capital.
  • WorkFusion, formerly Crowd Computing Systems, the leading enterprise crowd computing platform, in a $15 million Series B funding led by Mohr Davidow Ventures, with participation from existing investors, Greycroft Partners, iNovia Capital and RTP Ventures. The financing was followed by a venture debt financing by Silicon Valley Bank, bringing the total raise to $21 million.
  • NewSpring Capital in connection with its Series B investment in RightCare, an industry-leading medical technology company.
  • OrthoGenRx, a late stage product development company focused on the commercialization of generic Class III orthopedic medical devices, in a Series C financing, a Convertible Note financing and a Series A Participating Preferred financing.
  • ReliefBand Technologies LLC, a digital neurotechnology company that provides leading edge personalized medical treatment, in a $5 million Series A funding. The round was led by PathoCapital, a Chicago-based specialty health care fund. The investment will fuel the consumer market introduction of the company’s digital, FDA-cleared, wearable device for the drug-free treatment of nausea. The company’s technology was originally developed by Abbott Laboratories as part of its suite of oncology products.
  • PluroGen Therapeutics, an early stage biotechnology company that provides clinically advanced burn, wound and skin care products, in connection with a significant equity investment from and entering into a distribution agreement with Medline, Inc., a privately held manufacturer and distributor of medical devices and health care products.
  • Teckst, a company that provides text messaging software for enterprises, in a convertible note financing.
  • SIPP Eco Beverage Co., Inc., an all-natural and organic sparkling beverage brand, in its Series C-1 Preferred Stock equity financing. This was a follow-on investment to three prior rounds of equity financing and multiple debt financings by a New England-based venture capital firm.
  • Naturi, Inc, a premium organic food company, in its sale of Series A Preferred Stock.